Treatment failure in patients at high risk for prostate cancer is primarily local, with a markedly low metastatic failure incidence, researchers from the Southwest Oncology Group recently reported. Further, at all postsurgical PSA levels, additional radiation to the prostate bed lowers metastatic disease risk and biochemical failure.
Treatment failure in patients at high risk for prostate cancer is primarily local, with a markedly low metastatic failure incidence, researchers from the Southwest Oncology Group recently reported. Further, at all postsurgical PSA levels, additional radiation to the prostate bed lowers metastatic disease risk and biochemical failure.
A total of 431 patients with pathologically advanced prostate cancer after prostatectomy were randomized to additional radiotherapy or observation and were followed for a median of 10.2 years.
Of 374 men with a post-surgical PSA <0.2 ng/mL, treatment with radiation versus active surveillance was associated with lowered 10-year risk of biochemical treatment failure (72% to 42%), local failures (20% to 7%), and distant failures (12% to 4%). Among men whose postsurgical PSA was >0.2 but <1.0 ng/mL, 10-year risk of biochemical failure (80% to 73%), local failures (25% to 9%), and distant failures (16% to 12%) were reduced. Respective findings for patients with postsurgical PSA >1.0 ng/mL were 94% to100%, 28% to 9%, and 44% to 18%.
Study results were published in the Journal of Clinical Oncology (2007; 25:2225-9).
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Drug extends survival in prostate cancer with genetic mutations
December 8th 2023“Our analysis suggests that there is superior clinical benefit with olaparib versus control both in patients who had and had not received previous taxane treatment,” said Maha Hussain, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University.